Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIM: Optimization of Immunotherapy in Head and Neck Cancer
NCT03620123Phase 2Completed
- Sponsor
- AIO-Studien
- Start
- Jul 2018
- Primary completion
- Jun 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, ipilimumab in head and neck squamous cell carcinoma (HNSCC), sponsored by AIO-Studien. Started Jul 2018; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03620123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03620123.